This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Express Scripts to Boost Oral Medication With Diabetes Study
by Zacks Equity Research
Express Scripts' (ESRX) new study will support oral diabetes medication and reduce related costs.
IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex (LMNX) has a broad range of products that are built on advanced technology. Also, it has collaborative agreements with several companies, which should help expand the use of its products.
Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms
by Zacks Equity Research
The raised outlook for both Roto-Rooter unit and the bottom line indicate Chemed's (CHE) estimate of improved operating results in the upcoming quarters.
Illumina Teams Up With Telegraph Hill to Form Verogen
by Zacks Equity Research
Illumina (ILMC) and Telegraph Hill Partners plan to set up Verogen to accelerate adoption of NGS in the global forensic genomics market.
Veeva Systems (VEEV) Beats Q2 Earnings, Revenue Estimates
by Zacks Equity Research
Veeva Systems (VEEV) witnessed stellar numbers in the second quarter owing to strong adoption of products like Veeva Network, Veeva Align, Veeva OpenData and Veeva CRM Approved Email.
Align Technology-Patterson Dental Deal Expands iTero Reach
by Zacks Equity Research
Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.
LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track
by Zacks Equity Research
LabCorp's (LH) decision to buy the analytical testing services arm of ChromaDex should fortify its Covance Food Solutions business.
Stryker Recalls Sage Unit Products, Guidance Takes a Hit
by Zacks Equity Research
Added to the voluntary recall, Stryker (SYK) also placed a temporary hold on certain cloth-based products. Share price of Stryker declined massively following the news.
Patterson Companies (PDCO) Beats on Q1 Earnings, Keeps View
by Zacks Equity Research
Patterson Companies' (PDCO) Animal Health business continues to contribute to the bottom line. Stable fiscal 2018 guidance instills investor confidence.
Why IDEXX Laboratories (IDXX) Isn't Done Growing Earnings Yet
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
Civitas Solutions (CIVI) to Acquire Habilitative Services
by Zacks Equity Research
Civitas Solutions' (CIVI) proposed acquisition of Habilitative Services will aid the company in capturing the lucrative Minnesota market.
Accuray (ARAY) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.
Medtronic's (MDT) CE Mark in Heart Lead Strengthens CVG Arm
by Zacks Equity Research
Medtronic's (MDT) CVG arm continues to be the highest revenue grossing segment. Thus, the company's CE Mark receipt for Attain Stability Quad MRI SureScan Active-Fixation heart lead buoys optimism.
PerkinElmer Strong on Product Lineup Amid Integration Risks
by Zacks Equity Research
PerkinElmer's (PKI) expanding product portfolio helps it gain global market share. However, the company's regular acquisitions pose integration risks.
Medtronic (MDT) Beats Q1 Earnings, Misses Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) rides high in Q1 on strength in three major business segments.
PAREXEL Ties Up With Osaka International Cancer Institute
by Zacks Equity Research
We believe tie-ups like these will help PAREXEL (PRXL) drive its top and bottom line. The company also has a competitive edge in the Asia-Pacific markets.
Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife
by Zacks Equity Research
Cerner's (CERN) growth in order bookings would continue to boost growth prospects. However, steep competition in the HCIT space raise concern.
Quality Systems Professional Service a Drag, Competition Rife
by Zacks Equity Research
Quality Systems' (QSII) performance in the professional service business continues to be a drag in recent times. Also, macro headwinds continue to put pressure on performance.
Here's Why You Must Add Chemed (CHE) Stock to Your Portfolio
by Zacks Equity Research
Chemed Corporation's (CHE) promising Roto-Rooter revenue outlook as well as an increased bottom-line guidance bode well of the company's future.
BioScrip's Infusion Business Strong, Dull 2017 View a Drag
by Zacks Equity Research
BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.
Zimmer (ZBH) Plagued by Various Internal and External Issues
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.
Myriad Genetics' EndoPredict Gets Positive Coverage Decision
by Zacks Equity Research
Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.
Accuray's Radixact Now Used by Boise Summit Cancer Center
by Zacks Equity Research
Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.
Globus Medical's Robotic Guidance System Gets FDA Approval
by Zacks Equity Research
Positive tidings on the regulatory front have favored Globus Medical (GMED) of late. The company's latest regulatory progress would lend it a competitive edge in the global niche space.